title: The business of developing antibacterials.
abstract: Although some dazzling technical approaches have fallen short, dozens of small companies and a few major pharmas seek new products for this medically crucial, modest-growth market.
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Fox
mesh_terms: D000900:Anti-Bacterial Agents / Q000096:biosynthesis / Q000276:immunology*; D000918:Antibody Specificity / Q000276:immunology*; D001424:Bacterial Infections / Q000276:immunology / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D003132:Commerce; D015195:Drug Design; D004345:Drug Industry / Q000191:economics / Q000639:trends*; D004352:Drug Resistance, Microbial; D005380:Financing, Government; D016756:Immunoglobulins, Intravenous / Q000096:biosynthesis* / Q000627:therapeutic use; D016106:Methicillin Resistance / Q000187:drug effects / Q000276:immunology; D012109:Research Support as Topic; D013211:Staphylococcus aureus / Q000187:drug effects / Q000276:immunology
chemical_list: D000900:Anti-Bacterial Agents; D016756:Immunoglobulins, Intravenous